Channel Therapeutics (CHRO) Stock Analysis

What Channel Therapeutics does

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation. This compound is being explored for its potential efficacy in treating erythromelalgia and diverse forms of neuropathic pain. Founded in 2002, this New Jersey-based entity maintains its corporate headquarters in Freehold.

Key metrics

ETFs linked to CHRO

Broad-market and Healthcare sector ETFs an investor holding Channel Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CHRO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Channel Therapeutics?

Channel Therapeutics trades under the ticker CHRO on AMEX.

Which exchange is CHRO listed on?

CHRO is listed on AMEX.

What sector does Channel Therapeutics operate in?

Channel Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CHRO in a portfolio?

PortView shows CHRO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.